A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2a (40KD) (PEGASYS (R)) alone or in combination with lamivudine vs lamivudine in 546 patients with HBeAg-negative/anti-HBe-positive chronic hepatitis B.

Simple item page
dc.contributor.authorMarcellin, P.
dc.contributor.authorLau, G.
dc.contributor.authorBonino, F.
dc.contributor.authorFarci, P.
dc.contributor.authorHadziyannis, S.
dc.contributor.authorJin, R.
dc.contributor.authorLu, Z.
dc.contributor.authorPiratvisuth, T.
dc.contributor.authorGermanidis, G.
dc.contributor.authorYurdaydın, C.
dc.contributor.authorDiago, M.
dc.contributor.authorLai, M.
dc.contributor.authorButton, P.
dc.contributor.authorPluck, N.
dc.contributor.buuauthorGürel, S.
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi.tr_TR
dc.contributor.researcheridAAH-5364-2019tr_TR
dc.contributor.researcheridABI-3764-2020tr_TR
dc.date.accessioned2022-08-24T13:14:56Z
dc.date.available2022-08-24T13:14:56Z
dc.date.issued2003-10
dc.descriptionBu çalışma, 24-28 Ekim 2003 tarihleri arasında Boston, Massachusetts[Amerika Birleşik Devletleri]’nde düzenlenen 5. Annual Meeting of the Federation’da bildiri olarak sunulmuştur.tr_TR
dc.description.sponsorshipAmer Assoc Study Liver Diseasesen_US
dc.identifier.citationMarcellin, P. vd. (2003). “A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2a (40KD) (PEGASYS (R)) alone or in combination with lamivudine vs lamivudine in 546 patients with HBeAg-negative/anti-HBe-positive chronic hepatitis B”. Hepatology, 38(4), Supplement 1, 724A-725A.en_US
dc.identifier.endpage725Atr_TR
dc.identifier.issn0270-9139
dc.identifier.issue4, Supplement 1en_US
dc.identifier.startpage724Atr_TR
dc.identifier.urihttp://hdl.handle.net/11452/28349
dc.identifier.volume38tr_TR
dc.identifier.wos000185816701180
dc.indexed.wosSCIEen_US
dc.indexed.wosCPCISen_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.collaborationYurt içitr_TR
dc.relation.collaborationYurt dışıtr_TR
dc.relation.journalHematologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararasıtr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGastroenterology & hepatologyen_US
dc.subject.wosGastroenterology and hepatologyen_US
dc.titleA phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2a (40KD) (PEGASYS (R)) alone or in combination with lamivudine vs lamivudine in 546 patients with HBeAg-negative/anti-HBe-positive chronic hepatitis B.en_US
dc.typeMeeting Abstract
dc.wos.quartileQ1en_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science